MedTech. That's It.
How We Help
We work with PE funds, medical device companies, and established players across EMEA on everything from finding acquisition targets to preparing for exit. 13 services organized around the deal lifecycle: Find, Evaluate, Enter, Grow, Lead. Not sure what commercial DD is? Start here.
Before You Invest
Deal evaluation, target screening, and commercial diligence for acquisition and investment decisions.
Acquisition Target Screening
Finding the right acquisition target is harder than closing the deal. We help PE funds and MedTech companies build structured pipelines based on real strategic fit, not just database searches.
Our screening process combines 20+ years of MedTech market knowledge with actual market intelligence and proprietary networks. We go beyond databases. We assess commercial fundamentals, customer base quality, competitive position, and real growth trajectory. That means fewer wasted months chasing the wrong targets and a tighter pipeline from the start.
Who this is for
MedTech companies seeking bolt-on acquisitions, PE funds building MedTech portfolios, and corporate development teams running active Buy & Build strategies.
Engagement format
Project-based (6-10 weeks) or retainer for ongoing pipeline development.
Example deliverables
- Strategic target criteria definition
- Market mapping and long-list development
- Target profiling and commercial assessment
- Shortlist with prioritization rationale
- Approach strategy and outreach support
- Ongoing pipeline management
M&A Commercial Due Diligence
Private equity funds and strategic buyers rely on financial models. They should also understand the commercial reality. I dig into the questions that actually determine whether a deal creates value: Is the market growing? Is the competitive position real? Can the commercial engine actually scale?
I've managed P&Ls exceeding EUR 210M and led the integration of EUR 130M+ in acquisitions. I've sat on both sides of the table. I know what makes MedTech businesses work or fail after acquisition closes. That's the perspective I bring to commercial due diligence.
Who this is for
PE/VC funds evaluating MedTech targets, strategic acquirers planning bolt-on acquisitions, and portfolio companies preparing for exit.
Engagement format
Project-based, typically 3-6 weeks aligned to deal timelines.
Example deliverables
- Commercial due diligence report
- Market and competitive analysis
- Customer and KOL reference checks
- Revenue sustainability assessment
- Commercial value creation plan
- 100-day post-acquisition roadmap
Vendor Due Diligence
Selling a MedTech business requires more than clean financials. Buyers will pick apart your commercial fundamentals: market position, customer concentration, competitive threats, revenue sustainability. Vendor due diligence lets you address these questions proactively, on your own terms.
I prepare sell-side commercial reports that anticipate buyer concerns and present your business at its strongest. Market dynamics, competitive positioning, customer quality, revenue sustainability. I know exactly what PE funds and strategic buyers look for, because I run buy-side CDD for them. That's what makes vendor reports credible.
Who this is for
MedTech company owners preparing for exit, PE portfolio companies approaching sale, and corporate sellers divesting MedTech divisions.
Engagement format
Project-based (4-6 weeks), aligned to your sale timeline.
Example deliverables
- Vendor commercial due diligence report
- Market sizing and growth analysis
- Competitive positioning assessment
- Customer quality and concentration analysis
- Revenue sustainability validation
- Management presentation preparation
AI & Digital Due Diligence
MedTech is becoming more software-driven, and traditional commercial due diligence misses key questions about digital and AI capabilities. Is the AI clinically validated? Is the data strategy defensible? Can the digital product actually scale commercially?
Our AI & Digital DD evaluates the maturity, scalability, and commercial viability of digital health and AI capabilities within MedTech targets. We assess product-market fit, regulatory readiness (SaMD, MDR), data infrastructure quality, and the realistic path from technology to revenue.
This is not a technology audit. It is a commercial assessment of whether digital and AI capabilities will create value after acquisition, or become expensive distractions. We pair MedTech sector expertise with practical digital health commercialization experience to give investors clarity on what they are actually buying.
Who this is for
PE/VC funds evaluating MedTech targets with digital or AI components, strategic acquirers assessing technology capabilities, and corporate venture arms screening digital health investments.
Engagement format
Project-based (3-5 weeks), aligned to deal timelines.
Example deliverables
- AI and digital capability maturity assessment
- Product-market fit validation
- Data strategy and infrastructure evaluation
- Regulatory readiness review (SaMD, MDR)
- Commercial scalability analysis
- Technology risk and opportunity summary
PE/VC MedTech Investment Support
MedTech investing requires real sector knowledge. We work with PE/VC funds as a specialized resource throughout the investment lifecycle: from pre-deal screening and commercial due diligence, through portfolio company support and value creation, to exit preparation.
Our value is in translating operator experience into investor-relevant insights. We help funds ask the right questions, validate commercial assumptions, and build value creation plans that drive returns.
Who this is for
PE/VC funds with MedTech portfolios or deal pipelines, family offices evaluating healthcare investments, and corporate venture arms.
Engagement format
Retainer (ongoing sector advisory) or project-based (aligned to deal timelines).
Example deliverables
- Deal screening and sector mapping
- Commercial due diligence
- Value creation planning and execution
- Portfolio company board advisory
- Exit readiness assessment
- Industry expert introductions
Expert Network & Advisory Board Services
Sometimes you need a trusted perspective rather than a full engagement. We provide expert consultations for investors, consultancies, and corporations seeking senior MedTech insight on specific questions: market dynamics, competitive positioning, deal evaluation, or strategic direction.
We also design and run advisory boards for MedTech companies seeking structured external guidance on commercial strategy, market entry, or portfolio decisions.
Who this is for
Expert networks (GLG, AlphaSights, Guidepoint), management consultancies, investors conducting market studies, and MedTech companies building advisory boards.
Engagement format
Hourly consultations or structured advisory board programs.
Example deliverables
- Expert consultation calls
- Advisory board design and facilitation
- Strategic workshop facilitation
- Market landscape briefings
- Competitive intelligence sessions
Before You Expand
Market entry, go-to-market strategy, and commercial planning for growth and expansion.
Commercial Strategy & Go-to-Market Advisory
We help MedTech companies design and execute go-to-market strategies that actually drive growth. Entering a new European market? Launching a new product category? Restructuring your commercial model? We bring 20+ years of hands-on experience running commercial operations at global MedTech companies.
Our approach is rigorous analysis paired with practical execution. We assess market dynamics, reimbursement landscapes, competitive positioning, and channel strategies. Then we work with you to build a plan that actually works, not just sits in a document.
Who this is for
MedTech companies entering new European markets, launching new product lines, or seeking to accelerate growth in existing markets.
Engagement format
Project-based (typically 8-12 weeks) or ongoing advisory retainer.
Example deliverables
- Market sizing and opportunity assessment
- Competitive landscape analysis
- Channel strategy and partner selection
- Pricing and reimbursement strategy
- Go-to-market execution roadmap
- Sales force design and territory planning
Digital Health & AI Commercialization Advisory
The technology is rarely the bottleneck in digital health. Commercialization is. Regulatory pathways, reimbursement models, buyer personas, and procurement processes in healthcare are fundamentally different from traditional software or consumer tech markets.
We help digital health companies and MedTech innovators tackle the commercialization challenge. From defining the right business model to building clinical evidence strategies and engaging with payers, we connect innovation to market adoption.
Who this is for
Digital health startups and scale-ups, MedTech companies launching connected devices, and investors evaluating digital health opportunities.
Engagement format
Project-based (8-12 weeks) or ongoing advisory retainer.
Example deliverables
- Commercialization strategy and business model design
- Payer and reimbursement pathway analysis
- Clinical evidence and health economics planning
- Regulatory strategy alignment (MDR/IVDR)
- Buyer journey and persona mapping
- Pilot and scaling framework
Regulatory & Market Access Strategy
The European Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) have fundamentally changed the competitive landscape in European MedTech. Companies that treat regulatory compliance as purely a technical exercise miss the strategic implications for portfolio management, market access, and commercial planning.
We help MedTech companies understand and respond to the commercial impact of regulatory change. Our focus is on aligning regulatory strategy with commercial objectives to protect market position and capture new opportunities.
Who this is for
MedTech companies navigating MDR/IVDR transition, distributors rationalizing product portfolios, and manufacturers planning European market entry.
Engagement format
Project-based (6-10 weeks) or advisory retainer.
Example deliverables
- MDR/IVDR commercial impact assessment
- Portfolio rationalization strategy
- Market access and reimbursement planning
- Regulatory-commercial alignment roadmap
- Competitive positioning analysis post-MDR
- Distributor and channel strategy review
After You Acquire
Value creation, commercial transformation, and integration support post-acquisition.
Buy & Build Strategy
Buy & Build is the dominant value creation play in European MedTech PE. Most platforms struggle with the commercial side. Overlapping product lines, conflicting channels, customer confusion: all of this destroys value faster than acquisitions create it.
I help PE-backed MedTech platforms plan and execute the commercial dimension of Buy & Build. From defining the acquisition thesis through screening targets to post-deal integration and revenue synergy capture. I've managed commercial integration of EUR 130M+ in acquisitions. I know what it takes to make bolt-ons actually perform in practice, not just on paper. Each bolt-on is a commercial project, not just a financial transaction.
Who this is for
PE funds with MedTech platform investments, portfolio company management teams, and corporate development functions pursuing serial acquisitions.
Engagement format
Retainer (ongoing strategic advisory) or project-based per acquisition cycle.
Example deliverables
- Buy & Build commercial thesis development
- Bolt-on target screening and prioritization
- Commercial integration playbook
- Revenue synergy identification and tracking
- Channel harmonization strategy
- Post-acquisition commercial performance monitoring
Exit Readiness & Value Creation
The best time to prepare for exit is 12-18 months before you want to start the process. I help PE portfolio companies and founders build exit-ready commercial profiles by strengthening the metrics and narratives that drive valuation multiples.
That means finding and fixing commercial weaknesses before buyers uncover them. Customer concentration. Pricing vulnerabilities. Channel dependencies. Growth story gaps. I work with management teams to address these issues and build a data-backed growth narrative that actually holds up under buyer scrutiny.
My exit readiness work is hands-on, not just a strategic plan. I work alongside your team to improve commercial KPIs, restructure customer relationships, and build the proof points that maximize enterprise value.
Who this is for
PE portfolio companies 12-24 months from exit, MedTech founders planning a sale, and corporate sellers preparing MedTech carve-outs.
Engagement format
Retainer (12-18 months) or intensive project (8-12 weeks).
Example deliverables
- Commercial exit readiness assessment
- Value creation roadmap with prioritized initiatives
- Commercial KPI improvement program
- Equity story development
- Vendor due diligence preparation
- Management presentation coaching
Portfolio Value Creation
PE returns in MedTech increasingly come from operational value creation, not financial engineering. I work with portfolio company management teams to find and capture commercial value across pricing, channel optimization, market expansion, and product strategy.
I bring operator experience to this work. I've managed P&Ls exceeding EUR 210M, driven 27% revenue growth, and expanded market share by 19% in competitive MedTech segments. I embed within portfolio companies as an advisor who drives results, not just recommendations.
I focus on what actually moves enterprise value: pricing architecture, key account development, geographic expansion, commercial team effectiveness. Every initiative ties to measurable KPIs and tracked through structured reviews with the PE sponsor.
Who this is for
PE funds seeking commercial improvement in MedTech portfolio companies, portfolio company CEOs and CCOs, and investment teams building value creation plans.
Engagement format
Retainer (ongoing, typically 1-2 days/week) or project-based sprints.
Example deliverables
- Commercial value creation assessment (first 30 days)
- Prioritized initiative roadmap with P&L impact
- Pricing and margin optimization program
- Market expansion strategy
- Commercial team capability assessment
- Quarterly performance reviews with PE sponsor
Interim & Fractional Executive Leadership
Leadership transitions, organizational restructuring, and rapid scaling all require experienced hands at the helm. We provide interim and fractional executive leadership for MedTech companies that need senior commercial expertise without the time or commitment of a permanent hire.
Our interim engagements are not about keeping the seat warm. We drive change, build capability, and deliver results during the engagement period. Every interim assignment comes with a clear mandate, measurable objectives, and a structured handover plan.
Who this is for
MedTech companies in leadership transition, PE portfolio companies post-acquisition, and organizations scaling into new markets.
Engagement format
Interim (3-12 months, 3-5 days/week) or fractional (ongoing, 1-2 days/week).
Example deliverables
- Interim CCO, Country Manager, or VP Commercial role
- Organizational assessment and restructuring
- Team development and capability building
- Commercial process optimization
- KPI framework and performance management
- Structured handover to permanent leadership
Frequently Asked Questions
What is commercial due diligence and why does it matter?
Commercial due diligence is about figuring out whether the business actually works, not just the financials. Market position, customer quality, competitive threat, growth sustainability. Most deal value gets created or destroyed post-acquisition through commercial execution. That's why commercial DD matters.
What's included in your go-to-market strategy service?
We help you design and execute market entry strategies across Europe. Market sizing, competitive landscape, channel strategy, pricing, reimbursement, sales force design, and the execution roadmap to make it happen. We don't just write reports. We build plans with you and help you execute them.
How long do engagements typically take?
Project-based work (CDD, go-to-market, target screening) typically runs 6-12 weeks. Retainer arrangements are usually 1-2 days per week. Interim leadership is 3-12 months. Every engagement is built around your timeline and your needs.
Do you work with both buyers and sellers?
Yes. Buy-side commercial due diligence for PE funds and strategic buyers. Vendor due diligence for companies preparing to exit. Both sides benefit from clear-eyed assessment of commercial fundamentals before a deal closes.
What sectors and geographies do you focus on?
MedTech only. EMEA: Germany, Benelux, Nordics, UK, and emerging markets. No generalist experience, no learning curve. We know the regulatory dynamics, the reimbursement landscape, how distribution works in each market.
Can you help with digital health and AI commercialization?
Yes. We evaluate digital and AI capabilities for commercial viability, not technology risk. What matters is whether the tech actually drives value in healthcare. We also work on digital health commercialization strategy: regulatory pathways, payer engagement, how the buyer actually buys.
Not sure which service fits?
Every engagement is different. Tell us about your deal, your timeline, your challenge, and we'll figure out the right approach together.
Start a Conversation